TNFSF13B and systemic lupus erythematosus: Over six decades of clinical trials in SLE have only yielded one new therapy, belimumab, an inhibitor of the cytokine BAFF, with mixed efficacy in patients.11 Major failures of targeted therapy in the clinic for SLE11, 32, 33 suggest that breakthrough treatments may remain years away.